Imatinib: all 408 studies that test it
Page 2 of 5. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.
- Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast CancerTerminatedNCT00323063Phase 2Results posted
- Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to ImatinibTerminatedNCT00320190Phase 2Results posted
- Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00290771Phase 2Results posted
- Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit MutationCompletedNCT00278876Phase 2Results posted
- Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual DiseaseCompletedNCT00267085Phase 2Results posted
- A Study of Imatinib and Docetaxel in Prostate CancerCompletedNCT00251225Phase 2Results posted
- Imatinib Mesylate in Treating Patients With MyelofibrosisTerminatedNCT00245128Phase 2Results posted
- Neoadjuvant Imatinib in Dermatofibrosarcoma ProtuberansCompletedNCT00243191Phase 2Results posted
- A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit GeneCompletedNCT00237185Phase 2Results posted
- Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular ResponseTerminatedNCT00210119Phase 2Results posted
- Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell CarcinomaCompletedNCT00193258Phase 1/2Results posted
- Docetaxel Plus Imatinib Mesylate in Metastatic Breast CancerCompletedNCT00193180Phase 2Results posted
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 2Results posted
- An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 2Results posted
- An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast CrisisCompletedNCT00171158Phase 2Results posted
- Gemcitabine and Imatinib Mesylate as First-Line Therapy in Patients With Locally Adv. or Metastatic Pancreatic CancerCompletedNCT00161213Phase 2Results posted
- Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive GlioblastomaCompletedNCT00154375Phase 3Results posted
- Therapy for Newly Diagnosed Patients With Acute Lymphoblastic LeukemiaCompletedNCT00137111Phase 3Results posted
- Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)TerminatedNCT00124748Phase 3Results posted
- Trial Evaluating Gleevec in Patients With Anaplastic Thyroid CarcinomaTerminatedNCT00115739Phase 2Results posted
- Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCompletedNCT00103844Phase 2Results posted
- Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's SarcomaCompletedNCT00090987Phase 2Results posted
- S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast CancerCompletedNCT00087152Phase 2Results posted
- Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine CancerCompletedNCT00075400Phase 2Results posted
- Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced CancersCompletedNCT00074308Phase 1/2Results posted
- Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous LeukemiaActive, not recruitingNCT00070499Phase 2Results posted
- A Phase II Trial of STI571 in the Treatment of Metastatic Gastric CancerCompletedNCT00068380Phase 2Results posted
- Imatinib Mesylate in Treating Patients With Recurrent Brain TumorCompletedNCT00049127Phase 1/2Results posted
- Imatinib Mesylate in Treating Patients With Recurrent MeningiomaCompletedNCT00045734Phase 2Results posted
- Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaCompletedNCT00039377Phase 2Results posted
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
- Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CTerminatedNCT00038649Phase 2Results posted
- Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00038610Phase 2Results posted
- Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibCompletedNCT00036738Phase 2Results posted
- Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal TumorCompletedNCT00028002Phase 2Results posted
- Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00022490Phase 2Results posted
- Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent GliomaTerminatedNCT00021229Phase 1/2Results posted
- Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00015847Phase 2Results posted
- Pilot Study of Imatinib Cetuximab Combo for H & N CancerCompletedNCT05816785Early Phase 1
- A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgCompletedNCT05623774Phase 1
- Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingNCT05245968Phase 1
- Effect of Imatinib in Advance Liver Fibrosis PatientsStatus unknownNCT05224128Phase 1/2
- A Randomized Study to Investigate the Effect of Intravenous Imatinib on the Amount of Oxygen in the Lungs and Blood of Adults With COVID-19 Needing Mechanical Ventilation and Supportive Care.WithdrawnNCT04953052Phase 2
- Intravenous Imatinib in Mechanically Ventilated COVID-19 PatientsTerminatedNCT04794088Phase 2
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World PopulationActive, not recruitingNCT04626024Phase 2
- A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)Status unknownNCT04578847Phase 2
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingNCT04488081Phase 2
- The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced PneumoniaStatus unknownNCT04422678Phase 3
- Positioning Imatinib for Pulmonary Arterial HypertensionActive, not recruitingNCT04416750Phase 2
- Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19Status unknownNCT04346147Phase 2
- Treatments for COVID-19: Canadian Arm of the SOLIDARITY TrialStatus unknownNCT04330690Phase 3
- Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)Active, not recruitingNCT04138381Phase 1/2
- Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseActive, not recruitingNCT04070443Phase 2
- Entacapone Combination With Imatinib for Treatment of GISTCompletedNCT04006769Early Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib TreatmentStatus unknownNCT03862768Not applicable
- Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant ParasitesStatus unknownNCT03697668Phase 2
- Study of Imatinib in Children With Neurofibromatosis and Airway TumorsWithdrawnNCT03688568Phase 2
- Imatinib for Multiple Sclerosis (MS) RelapsesStatus unknownNCT03674099Phase 2
- Imatinib in Acute Ischaemic StrokeStatus unknownNCT03639922Phase 3
- PDR001 Plus Imatinib for Metastatic or Unresectable GISTCompletedNCT03609424Phase 1/2
- Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
- A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.TerminatedNCT03469011Phase 1
- Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT03343600Phase 2
- A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung InjuryCompletedNCT03328117Phase 1
- The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous LeukaemiaStatus unknownNCT03241199Phase 2
- Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid LeukemiaStatus unknownNCT03228303Early Phase 1
- KISS Study: Kinase Inhibition With Sprycel Start upActive, not recruitingNCT03193281Phase 2
- Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric CancerCompletedNCT03170180Phase 2
- Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 StudyStatus unknownNCT02894645Phase 4
- Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the HostCompletedNCT02891395Phase 2
- Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
- A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTsCompletedNCT02712112Phase 2
- Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous LeukemiaStatus unknownNCT02687425Phase 2
- Imatinib as Pre-operative Anti-Colon Cancer Targeted TherapyTerminatedNCT02685046Phase 2
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum MalariaCompletedNCT02614404Phase 1
- Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
- A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)CompletedNCT02495519Phase 2
- Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCLTerminatedNCT02462538Phase 1/2
- Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib TherapyStatus unknownNCT02461849Phase 2
- Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GISTActive, not recruitingNCT02413736Phase 3
- Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility StudyStatus unknownNCT02363361Phase 2
- Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular ResponseCompletedNCT02326311Phase 3
- Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid LeukemiaStatus unknownNCT02317159Phase 4
- Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural MesotheliomaCompletedNCT02303899Phase 2
- Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal TumorsWithdrawnNCT02268435Phase 1
- Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)CompletedNCT02260505Phase 3
- Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform NeurofibromasTerminatedNCT02177825Phase 2
- An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two YearsTerminatedNCT02174445Phase 3
- Explore the Synergy of Combination TKI TherapyWithdrawnNCT02129166Phase 1
- Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsCompletedNCT02103322Phase 2/3
- A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC StudyStatus unknownNCT02013089Not applicable
- Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid LeukaemiaCompletedNCT02001818Phase 2
- MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)Active, not recruitingNCT01991379Phase 1/2
- Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in ChildrenTerminatedNCT01898377Phase 2
- Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment IntoleranceCompletedNCT01819389Phase 3
- De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid LeukaemiaCompletedNCT01804985Phase 2
- A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated MelanomaStatus unknownNCT01782508Phase 2